Latest TB Stories

In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease. The drug rifampin, used for treating TB, can lower levels of the HIV medicine efavirenz, so the FDA recommended that patients who weigh more than 50 kg (110 pounds) and who are taking both medications should get 30...

RARITAN, N.J., July 2, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults. If approved by the FDA, bedaquiline would be the first drug...

Inhibiting immune response early on could speed treatment time, prevent relapse Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could — paradoxically — shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children's Center and the Center for TB Research. Shorter duration of drug therapy is key, researchers say, to increase treatment compliance for the growing global health threat...

TB infections, a serious threat to monkeys and apes, previously had been difficult to detect Tuberculosis can be a serious threat to monkeys and apes. A new technique for detecting the tuberculosis-causing bacteria could help in protecting the health of primate populations. The method can spot TB even among infected primates that show no outward sign of disease, but are still capable of spreading infection to others of their kind. Existing tests for TB in primates are difficult to...

Immune Network Ltd. (IMMFF), announces the completion of a Phase II trial of a once-daily M. vaccae pill (V7) conducted by Immunitor in Ukraine. The imm02 study was aimed to seek whether oral formulation of inactivated whole cell mycobacteria can shorten TB treatment duration. Vancouver, Canada (PRWEB) June 17, 2012 The phase II, placebo-controlled trial, conducted by experts in the field of TB immunotherapy, was set to evaluate the efficacy of tableted, heat-killed Mycobacterium vaccae...

SAN FRANCISCO, June 12, 2012 /PRNewswire/ -- Medizone International, Inc. (The Company) (MZEI:OB) (MZEI:QB) announced today that in achieving 100% kill rates with TB in three successive trials, it had achieved another important milestone in its understanding of the antimicrobial limits of its recently launched disinfection technology, AsepticSure(TM). Dr. Michael E Shannon, President of Medizone International, stated, "With one third of the world's population currently infected...

Apramycin, already used in animals, shows promise against drug-resistant TB and other 'superbugs,' without hearing loss The world needs new antibiotics to overcome the ever increasing resistance of disease-causing bacteria – but it doesn't need the side effect that comes with some of the most powerful ones now available: hearing loss. Today, researchers report they have developed a new approach to designing antibiotics that kill even "superbugs" but spare the delicate sensory cells of...

Apramycin, already used in animals, shows promise against drug-resistant TB and other "superbugs", without hearing loss ANN ARBOR, Mich., June 11, 2012 /PRNewswire-USNewswire/ -- The world needs new antibiotics to overcome the ever-increasing resistance of disease-causing bacteria - but it doesn't need the side effect that comes with some of the most powerful ones now available: hearing loss. Today, researchers report they have developed a new approach to designing antibiotics that...

BRONX, N.Y., May 31, 2012 /PRNewswire-USNewswire/ -- The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered...

Tuberculosis, now largely controlled in the industrialized world, remains a stubbornly persistent killer in most of Africa, as well as parts of Asia and South America. The spread of multidrug-resistant strains of TB has slowed progress against the devastating disease, which is estimated to strike more than 10 million people annually. Now a modified soft-drink cooler, developed by researchers at MIT’s D-Lab, could make a dent in the disease’s impact. There are two big issues that...